Table 1.
MicroRNAs involved in drug resistance.
| Type of resistance | microRNAs | Cancer | Drug | Targets | References |
|---|---|---|---|---|---|
| Drug efflux | miR-519c | Colon cancer | MXR | ABCG2 | To et al. (2008) |
| miR-212 | CML | Imatinib | ABCG2 | Turrini et al. (2012) | |
| miR-27a | Gastric cancer | ADR | P-glycoprotein | ||
| miR-101/135 | HCC | N. R. | ABCA1 | Borel et al. (2012) | |
| miR-199a/b/-296 | HCC | N. R. | ABCC1 | Borel et al. (2012) | |
| miR-125a/b | HCC | N. R. | ABCC4 | Borel et al. (2012) | |
| miR-101/125a/let-7a | HCC | N. R. | ABCC5 | Borel et al. (2012) | |
| Let-7a/e | HCC | N. R. | ABCC10 | Borel et al. (2012) | |
| miR-26a/-135b/-145 | HCC | N. R. | ABCE1 | Borel et al. (2012) | |
| miR-379 | HCC | Rifampicin | ABCC2 | Haenisch et al. (2011) | |
| miR-328 | Breast cancer | MXR | ABCG2 | Pan et al. (2009) | |
| miR-200c | Breast cancer | ADX | MDR1/P-glycoprotein | Chen et al. (2011a,b) | |
| miR-326 | Breast cancer | VP-16/ADX | MRP-1 | Liang et al. (2009) | |
| miR-451 | Breast cancer | Irinotecan | ABCB1 | Bitarte et al. (2011) | |
| miR-199a | Ovarian cancer | CDD/PTX/ADR | ABCG2 | Cheng et al. (2012) | |
| MiR-27a | Ovarian cancer | PTX | MDR1/P-gp | Li et al. (2010) | |
| Alterations in drug targets | miR-485-3p | ALL | TopII inhibitors | NF-YB | Chen et al. (2011a,b) |
| miR-143/145 | Liposarcoma | N. R. | Top2a | Ugras et al. (2011) | |
| miR-100 | Breast cancer | PTX | β-Tubulin I, IIA, IIB, V | Lobert et al. (2011) | |
| miR-148a | Prostate cancer | N. R. | MSK1 | Fujita et al. (2010) | |
| miR-7 | Lung cancer | TKIs | EGFR | Rai et al. (2011) | |
| miR-30c/221/222 | Lung cancer | TKIs | BIM/APAF-1 | Garofalo et al. (2011) | |
| miR-103/203 | Lung cancer | TKIs | PKC-ε/SRC | Garofalo et al. (2011) | |
| DNA repair | miR-138 | Lung cancer | CDD | ERCC1 | Wang et al. (2011) |
| miR-182 | Breast cancer | PARP1 inhibitor | BRCA1 | Moskwa et al. (2011) | |
| miR-21 | Colon cancer | 5-FU | hMSH2-hMSH6 | Valeri et al. (2010) | |
| miR-21 | Breast cancer | CDD, ADX | HMSH2 | Yu et al. (2010) | |
| Cell cycle | miR-200 | Lung | DOC | E2F3 | Feng et al. (2012) |
| miR-19b/21 | Colon cancer | 5-FU | SFPQ, MYBL2 | Kurokawa et al. (2012) | |
| miR-215 | Colon cancer | MTX, TDX | DTL | Song et al. (2010) | |
| Osteosarcoma | |||||
| miR-34a | Prostate cancer | Camptothecin | CDK6, cyclin D1, E2F3, E2F1 | Fujita et al. (2008) | |
| miR-221/222 | Breast cancer | Fulvestrant | p27 Kip1 | Rao et al. (2011) | |
| miR-221/222 | Breast cancer | TAM | p27 Kip1 | Miller et al. (2008) | |
| Evasion of apoptosis | miR-181a/b | CLL | Fludarabine | MCL-1, Bcl2 | Zhu et al. (2010a,b) |
| miR-497 | Breast cancer | N. R. | Bcl-w | Shen et al. (2012) | |
| miR-136 | Glioma | CDD | AEG-1, Bcl-2 | Yang et al. (2012) | |
| miR-200b/c/429 | Gastric cancer | CDD, VCR | Bcl-2, Xiap | Zhu et al. (2012) | |
| miR-497/181 | Gastric cancer | CDD, VCR | Bcl2 | Zhu et al. (2010a,b, 2011) | |
| miR-34a | Gastric cancer | ADX, CDD, GEM, DOC | Bcl2 | Ji et al. (2008) | |
| miR-15/16 | Gastric cancer | ADR, VP-16, CDD | Bcl-2 | Xia et al. (2008) | |
| miR-512-3p | HCC | TXL | c-Flip | Chen et al. (2010) | |
| miR-21 | GBM | N. R. | Bcl-2/Bax ratio | Shi et al. (2010) | |
| miR-34c-5p | NSCLC | TXL | Bmf | Catuogno et al. (2012) | |
| miR-24 | NSCLC | TRAIL | Xiap | Xie et al. (2012) | |
| miR-25 | Cholangiocarcinoma | TRAIL | DR4 | Razumilava et al. (2012) | |
| miR-221/222 | NSCLC | TRAIL | PTEN, TIMP3 | Garofalo et al. (2009) |
DOC: docetaxel; CDD: cisplatin; TRAIL: TNF-related apoptosis inducing ligand; TKIs: tyrosine kinase inhibitors; 5-FU: fluorouracil; ADX: doxorubicin; TXL: taxolo; VP-16: etoposide; MXR: mitoxantrone; TAM: tamoxifen; ADR: adriamycin; VCR: vincristine; GEM: gemcitabine; PTX: paclitaxel; TMZ: temozolomide; TDX: tomudex; CML: chronic myeloid leukemia; HCC: hepatocarcinoma; GBM: glioblastoma multiforme; ALL: acute lymphoblastic leukemia; CLL: chronic lymphocytic leukemia. N. R.: not reported.